Biohaven Pharmaceutical, a biopharma company with a portfolio of late-stage candidates targeting neurological diseases including rare disorders, has appointed Vlad Coric, MD, Chairman of the Board of Directors following the retirement of Declan Doogan, MD, effective immediately. The company also appointed Matthew Buten as Chief Financial Officer, following the retirement of CFO James Engelhart. Both Dr. Doogan and Mr. Engelhart will continue to advise the company after their retirement to ensure...